Posts
- Beacon 2024 Product Milestones, and a look ahead to 2025.
- Beacon ADC Cited in mAbs Journal
- Beacon Launches Immune Tolerance Dataset
- Beacon Launches Oncology Deals and Companies Data Expansion
- Beacon RNA Cited in Nature, NPJ Genomic Medicine
- Introducing Beacon Oncology: The Most Comprehensive Oncology Drug Development Database.
Pages
Solutions
- Beacon ADC Database
- Beacon Autoimmune Database
- Beacon Bispecific Database
- Beacon Cancer Vaccine Database
- Beacon Cell Therapy Database
- Beacon Checkpoint Database
- Beacon Cytokine
- Beacon DDR Database
- Beacon Gene Therapy Database
- Beacon Microbiome Database
- Beacon Oncology Database
- Beacon Oncolytic Viruses Database
- Beacon RNA Database
- Beacon TPD Database
Events
- 15th Clinical Biomarkers & CDx Summit Europe 2025
- 4th Next Generation Gene Therapy Vectors 2025
- 4th World ADC Asia Summit 2025
- 6th Cytokine-Based Drug Development Summit 2025
- ADC Partnering & Investment Summit
- The 10th CAR-TCR Summit
- The 16th World Bispecific Summit
- The 5th Annual mRNA Based Therapeutics Summit
Webinars
- AACR 2024: DDR Related Abstracts
- ADC and Immune Checkpoint Combination Therapies
- Allogeneic Cell Therapy Innovations
- Bispecific Antibodies and Immune Checkpoint Modulators
- Bivalent Degrader Landscape
- Cell Therapy Commercial Research Landscape
- Cytokine Based Drug Development Landscape
- Drug Payload Quantification in LNPs with New Scatter-Free Absorption
- Inflammatory Bowel Disease Drug Market Trends
- Liquid Biopsy Landscape: CtDNA in Lung Cancer Research
- Microbiome Targeting Therapeutics in Infectious Disease
- Navigating Payload Innovation and Toxicity Trends in ADC Development
- Novel Drug Conjugates and Clinical Success: An In-Depth Analysis of Emerging ADCs
- Optimizing Next Generation Viral Vector Safety
- Pioneering New Treatment Options in Relapsed or Refractory Multiple Myeloma with a New Amanitin-based ADC
- Review of the Induced Proximity Landscape
- STING TLR Landscape Review
- The ADC Landscape
- The RNA Gene Therapy Landscape
- The Road Ahead for Addressing Autoimmune Indications with T Cell Therapies
- TPD Disease Landscape
- Unlocking the Future of RNA Therapeutics: Delivery System Evolution, Preclinical Insights, and Market Impact
Infographics
- AACR 2025: A Spotlight on New Drugs
- ADC Pre-Clinical Development: Where Are We in 2023?
- ADCs in the Oncology Landscape
- ASCO 2023: TPD Landscape Overview
- ASCO 2024: ADC Highlights
- ASCO 2024: Bispecific Highlights
- ASCO 2024: Checkpoint Highlights
- ASCO 2024: Cytokine Highlights
- Checkpoint Targeting Bispecifics
- DDR Combination Therapies
- Exploring Human Papillomavirus
- Exploring The Synergy Of ADC’s And DDRi’s in Cancer Therapy
- Liquid Biopsy Assays For ctDNA Detection
- Lysosomal Storage Diseases – A Comprehensive Overview
- Microbiome Drug Development in Asia
- Microbiome Drug Development Milestones
- Microbiome Therapeutics and Preclinical Models
- Neoantigen Cancer Vaccines
- Next Generation TPD Degraders
- Next-Gen Therapies: Unlocking the Potential of Bispecific ADCs
- T Cell Engagers: Revolutionizing Autoimmune Disease Treatment
- The Adenosine Pathway Clinical Trial Landscape
- The Molecular Glue Landscape
- The mRNA-Based Therapy Landscape
- The Oncology Deals and Companies Landscape
- The Rise of Bispecific Combination Trials
- Unlocking the Potential of mRNA Cancer Vaccines
Landscape Reviews
- ADC Landscape Review
- Bispecific Landscape Review
- Cancer Vaccine Landscape Review
- Cell Therapy Landscape Review
- Checkpoint Landscape Review
- Cytokine Landscape Review
- DDR Landscape Review
- Gene Therapy Landscape Review
- Immune Tolerance Landscape Review
- Microbiome Landscape Review
- Oncology Landscape Review
- Oncolytic Viruses Landscape Review
- RNA Landscape Review
- TPD Landscape Review
Conference Reports
- AACR 2023: ADC Post-Conference Report
- AACR 2023: Bispecific Post-Conference Report
- AACR 2023: Cancer Vaccine Post-Conference Report
- AACR 2023: Checkpoint Post-Conference Report
- AACR 2023: Cytokine Post-Conference Report
- AACR 2023: Oncolytic Viruses Post-Conference Report
- AACR 2024: DDR Post-Conference Report
- AACR 2024: RNA Post-Conference Report
- AACR 2024: TPD Post-Conference Report
- AACR 2025: ADC Pre-Conference Planner
- AACR 2025: Bispecific Post-Conference Report
- AACR 2025: Cell Therapy Post-Conference Report
- AACR 2025: Cytokine Post-Conference Report
- AACR 2025: RNA Pre-Conference Planner
- AACR 2025: TPD Post-Conference Report
- AACR NCI EORTC: DDR Post-Conference Report
- ASCO 2023: ADC Post-Conference Report
- ASCO 2023: Bispecific Post-Conference Report
- ASCO 2023: Cancer Vaccine Post-Conference Report
- ASCO 2023: Cell Therapy Post-Conference Report
- ASCO 2023: Checkpoint Post-Conference Report
- ASCO 2023: Cytokine Post-Conference Report
- ASCO 2023: Oncolytic Viruses Post-Conference Report
- ASCO 2023: TPD Post-Conference Report
- ASCO 2024: Cancer Vaccine Post-Conference Report
- ASCO 2024: DDR Post-Conference Report
- ASCO 2024: Oncolytic Viruses Post-Conference Report
- ASCO 2024: TPD Post-Conference Report
- ASCO 2025: Cell Therapy Post-Conference Report
- ASCO 2025: Cytokine Post-Conference Report
- ASCO 2025: TPD Conference Report
- ASGCT 2024: Advanced Therapies Post-Conference Report
- ASGCT 2024: Cell Therapy Post-Conference Report
- ASGCT 2024: Gene Therapy Post-Conference Report
- ASGCT 2025: Cell Therapy Post-Conference Report
- ASGCT 2025: Gene Therapy Post-Conference Report
- ASGCT 2025: RNA Post-Conference Report
- ASH 2023: Cell Therapy Post-Conference Report
- ASH 2023: Gene Therapy Post-Conference Report
- ASH 2024: ADC Post-Conference Report
- ASH 2024: Cell Therapy Post Conference Report
- ESMO 2023: Checkpoint Post-Conference Report
- ESMO 2023: Cytokine Post-Conference Report
- ESMO 2023: DDR Post-Conference Report
- EULAR 2024: Immune Tolerance Post-Conference Report
- EULAR 2025: Autoimmune Post-Conference Report
- SITC 2023: Cancer Vaccine Post-Conference Report
- SITC 2023: Cell Therapy Post-Conference Report
- SITC 2023: Oncolytic Viruses Post-Conference Report
- SITC 2023: RNA Post-Conference Report
- SITC 2024: Bispecific Post-Conference Report
Market Reports
- A Spotlight on the TGF-β Cancer Clinical Trial Landscape
- Armored Cell Therapies
- Cytokine-Armoured Cell Therapies: Overcoming Immunosuppression and Improving Persistence
- Deals & Companies Report: Global Commercial Insights From The Biologics Market
- Delving Deeper into Allergy Drug Development:
- Disease Trends in the Oligonucleotide Space
- Global Commercial Insights From the Bispecific and Multispecific Market
- In Vivo CAR Therapies: Review of a Novel Modality
- Investment Trends in Early Stage BioPharma
- Monoclonal Antibodies (mAbs) Unveiled: A Comprehensive Review of the Landscape in Immune-Mediated Diseases
- Navigating the Complex Landscaspe of Skysona and Hematologic Cancer
- Oncolytic Viruses: Monotherapies vs. Combination Therapy
- PD-L1: An Endless Classic or Passing Fancy?
- Pre-Clinical Cytokine Drug Development: An Analysis of the Latest Data
- Strategic Insights for Biopharma Innovation
- The Checkpoint Disease Landscape: Exploring the Top Cancer Indications
- The Colorectal Cancer Landscape
- The Evolving Brain Cancer Landscape
- The Latest Breakthrough in Autoimmune Therapy
- The Oligonucleotide Landscape
- The Power of Precision: Exploring Editing Technologies in Gene Therapy
- The Rise of ADCs and Novel Drug Conjugates in Asia
- The US Market and LBP Development
- TIGIT Axis Therapies and The Cancer Clinical Trial Landscape
- Treg Therapies in Autoimmune Diseases
- Trends and Challenges in Early-Stage Cytokine-Based Drug Development Commercialization
- VEGF PDL-1 Multispecifics Report
APIs
Market Research
- News
Categories
Search